| 000 | 01602 a2200445 4500 | ||
|---|---|---|---|
| 005 | 20250517033028.0 | ||
| 264 | 0 | _c20160502 | |
| 008 | 201605s 0 0 eng d | ||
| 022 | _a1876-4479 | ||
| 024 | 7 |
_a10.1093/ecco-jcc/jjv090 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aErim, Daniel O | |
| 245 | 0 | 0 |
_aThe Value of Vedolizumab as Rescue Therapy in Moderate-Severe Crohn's Disease Patients with Adalimumab Non-response in the USA. _h[electronic resource] |
| 260 |
_bJournal of Crohn's & colitis _cAug 2015 |
||
| 300 |
_a669-75 p. _bdigital |
||
| 500 | _aPublication Type: Evaluation Study; Journal Article | ||
| 650 | 0 | 4 |
_aAdalimumab _xeconomics |
| 650 | 0 | 4 |
_aAnti-Inflammatory Agents _xeconomics |
| 650 | 0 | 4 |
_aAntibodies, Monoclonal, Humanized _xeconomics |
| 650 | 0 | 4 | _aComputer Simulation |
| 650 | 0 | 4 |
_aCrohn Disease _xdrug therapy |
| 650 | 0 | 4 | _aDrug Administration Schedule |
| 650 | 0 | 4 |
_aDrug Costs _xstatistics & numerical data |
| 650 | 0 | 4 | _aDrug Therapy, Combination |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMarkov Chains |
| 650 | 0 | 4 | _aModels, Biological |
| 650 | 0 | 4 | _aModels, Economic |
| 650 | 0 | 4 | _aModels, Statistical |
| 650 | 0 | 4 | _aQuality of Life |
| 650 | 0 | 4 | _aSeverity of Illness Index |
| 650 | 0 | 4 | _aTreatment Failure |
| 650 | 0 | 4 | _aTreatment Outcome |
| 650 | 0 | 4 | _aUnited States |
| 700 | 1 | _aMahendraratnam, Nirosha | |
| 700 | 1 | _aOkafor, Phillip N | |
| 700 | 1 | _aWheeler, Stephanie B | |
| 773 | 0 |
_tJournal of Crohn's & colitis _gvol. 9 _gno. 8 _gp. 669-75 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1093/ecco-jcc/jjv090 _zAvailable from publisher's website |
| 999 |
_c24913613 _d24913613 |
||